October 27-29, 2020 | Digital Event

9.00AM - 5.30PM EDT | 6.00AM - 2.30PM PDT

www.protein-misfolding.com

BOOK BY JULY 31 TO SAVE UP TO $600



Protein Misfolding Drug Discovery

Digital

Discover & Translate Disease-Modifying Therapeutics that Target Misfolded & Oligomeric Proteins to Transform Clinical Outcomes in Neurodegeneration & Beyond

Expert Speakers Include:

Matthew Townsend
Global Director of Proteostasis, Alzheimer's Disease
AbbVie

Aubin Michalon
Principal Scientist
Neurimmune

Robert Scannevin
VP, Discovery Biology
Yumanity

Michele Vendruscolo
Professor & CSO Cambridge University Centre for Misfolding Diseases & **Wren Therapeutics**

Beth Hoffman
Founder, President & CEO
Origami Therapeutics

Marcia Taylor
VP Research & Neurodegeneration Alliance Manager
Treventis

Rick Morimoto
Professor
Northwestern University

Neil Cashman
CSO & Co-Founder
ProMIS Neurosciences

Wagner Zago
CSO
Prothena

Proud to Partner With: StressMarq Biosciences Inc. | dynamic BIOSENSORS | SOLA BIOSCIENCES

+1 617 455 4188 info@hansonwade.com

hansonwade

Welcome to the Digital Protein Misfolding Drug Discovery Summit

With protein misfolding and aggregation prevalent in neurodegeneration, cancer, metabolic and ophthalmic diseases, this presents huge patient and product opportunity. However, decades of clinical lessons and revived investment in understanding the molecular biology of protein misfolding disorders, has failed to yield clinically meaningful therapies targeting misfolded or oligomeric proteins.

The **Digital Protein Misfolding Drug Discovery Summit** arrives as the definitive forum for large pharma, innovative biotech and research institutes to shift the drug discovery paradigm and seize the untapped opportunity of protein misfolding targeted therapeutics.

This Summit will unite drug discovery and development professionals to **validate novel misfolded and oligomeric protein targets underlying neurodegeneration and beyond, improve preclinical predictability of patient derived models, optimize drug pharmacology** and **accelerate the translation of novel protein misfolding targeted therapeutics**.

With numerous candidates poised to enter the clinic, join the **Digital Protein Misfolding Drug Discovery Summit - the only industry and translational focused conference**, dedicated to discover and translate disruptive disease-modifying therapeutics targeting misfolded and oligomeric proteins in neurodegeneration and beyond.

Why our speakers are so excited:

"At last, a comprehensive industrial-academic meeting on treating protein misfolding diseases!"

Neil Cashman, ProMIS Neurosciences

"I am looking forward to the first event on drug discovery for protein misfolding diseases, which will bring together major players in this area. It will be a great opportunity for discussing and prioritizing targets and methods."

Michele Vendruscolo, Cambridge University & Wren Therapeutics

Why Attend the Digital Protein Misfolding Drug Discovery Summit?

Discover the latest understanding of different molecular approaches towards targeting protein misfolding with insights from **Prothena, Origami Therapeutics** & **Stanford University**

Overcome preclinical challenges for robust translation of protein misfolding therapeutic candidates into the clinic with insights from **AbbVie** & **Eli Lilly**

Understand different drug modalities such as immunotherapies, small molecules and peptide-based approaches to accelerate your candidates to clinic with insights from **ProMIS Neurosciences**, **CantaBio Pharmaceuticals** & **Aelin Therpaeutics**



Leverage cross-learnings from clinical case studies to successfully and robustly translate your drug candidates into different clinical indications with insights from **Anavex Life Sciences** & **Lysosomal Therapeutics**

Join the momentum to reverse the undruggable nature of misfolded proteins and aggregates with insights from **Yumanity** & **Wren Therapeutics**

YOUR EXPERT SPEAKERS

Matthew Townsend
Global Director of Proteostasis, Alzheimer's Disease
AbbVie

John Hey
CSO
Alzheon

Christopher Missling
President & CEO
Anavex Life Sciences

Michele Vendruscolo
Professor & CSO Cambridge University Centre for Misfolding Diseases & **Wren Therapeutics**

Gergely Tóth
Founder & CEO
CantaBio Pharmaceuticals

Behnam Nabet
Postdoctoral Research Fellow, Gray Lab
Dana-Farber Cancer Institute

Ulrich Rant
CEO
Dynamic Biosensors

David Lynn
HHMI Professor
Emory University

Zhexing Wen
Assistant Professor
Emory University

Giulio Pasinetti
Chair & Professor of Neurology
Icahn School of Medicine at Mount Sinai

Peter Lansbury
CSO
Lysosomal Therapeutics

Aubin Michalon
Principal Scientist
Neurimmune

Rick Morimoto
Professor
Northwestern University

Beth Hoffman
Founder, President & CEO
Origami Therapeutics

Neil Cashman
CSO & Co-Founder
ProMIS Neurosciences

Wagner Zago
CSO
Prothena

Akinori Hishiya
Founder & CSO
SOLA Biosciences

Judith Frydman
Professor
Stanford University

Ariel Louwrier
President & CEO
StressMarq Biosciences Inc.

Marcia Taylor
VP Research & Neurodegeneration Alliance Manager
Treventis

David Smith
Associate Professor
West Virginia University

Johnny Habchi
Head of Research
Wren Therapeutics

Robert Scannevin
VP, Discovery Biology
Yumanity

"We are dealing with extremely challenging diseases and this requires a joined-up approach to deliver very much needed solutions. It is the right time for everyone to come together and accelerate drug discovery for these debilitating diseases"
Johnny Habchi, Wren Therapeutics

An Interactive Online Experience

The **Digital Protein Misfolding Drug Discovery Summit** is committed to delivering the high-quality insights and industry connections that our customers expect, in a format that is accessible from the comfort of your home or office.

We have created the digital summit to satisfy the industry's need to share cutting-edge research, learn from your peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.

To effectively facilitate this need to learn and connect, our custom-built digital event platform will combine best-in-class platforms to deliver a seamless event experience. Accessing the platform is simple, you'll be provided with a unique link in the run up to the event that will take you directly to the online event space where you'll follow a few simple steps to set up your delegate profile and get started.

KEY FEATURES OF THE DIGITAL SUMMIT

Our mission remains dedicated to ensuring the protein misfolding community have the tools and the means to advance their research and knowledge of the field. Although we may not meet in person, we uphold our promise to unite the protein misfolding community.

Whilst face-to-face meetings are put on hold, we continue to deliver the key features of a physical meeting in an optimal digital world:

Delegate Profile
Set up personalized profiles to easily identify the name, job title and company of other attendees

Stage Area
Most presentations will be delivered in the 'stage' area, much like the main conference room onsite

Sessions Area
Smaller groups can get together in this breakout area for panel discussions and other interactive sessions

Demo Area
Visit the virtual exhibition area to explore the solutions our specialist vendors have on offer

Chat Rooms
Connect with your peers and start conversations with individuals or all attendees in private and public chatrooms

Speed Networking
This virtual networking session will connect you with other attendees to establish new industry contacts

WHAT CAN YOU EXPECT?

Live Q&A

Ask your questions directly to presenters in real-time, just as you would face-to-face. Make your voice heard and jump on the screen to share your thoughts

Audience Discussions

Interactive speed networking will allow you to meet and network with your peers. In addition, join our informal "meeting rooms" where up to 10 guests can join an interactive and informal chat

Virtual Exhibition Hall

Take a tour around our virtual exhibition hall. Leading vendors will be waiting to show you how they can aid your disease modifying therapies into clinic. Easily exchange business cards to keep the conversation going!

Private Message Attendees

Grab an old colleague or a new connection and invite them to a personal meeting room. Using our bespoke chat function, you can see all attendees in real-time and invite them for a conversation

+1 617 455 4188 info@hansonwade.com
www.protein-misfolding.com
hansonwade

PRE-CONFERENCE WORKSHOP DAY TUESDAY | OCTOBER 27

9.30AM - 4.00PM EDT I 6.30AM - 1.00PM PDT

9.30 | 6.30 Online Registration & Virtual Coffee Networking

Workshop A

10.00 | 7.00

Leveraging Pathobiology of Self-Perpetuating Amyloid Strains for Translational Protein Misfolding Targeted Therapeutics

For most of the past 70 years of molecular biology, amino acid sequences encoded in genomic DNA and environmental context have been the primary consideration for functional protein folding. However, many proteins acquire alternative conformations and proceed through two-step nucleation to achieve paracrystalline variants that can faithfully reproduce, for example in case of self-perpetuating cross-β fibrils (amyloids). These amyloids are associated with more than 40 devastating diseases, including Alzheimer's disease and various systemic and localized amyloidoses. Recent evidence suggests that amyloids can exist as structural and functional variants called strains, but surprisingly little is known about the steps at which strain formation is controlled, the molecular mechanisms underlying strain patterns, or the role of polymorphic strains in pathogenicity. Our goal in the workshop will be to inform therapeutic strategies for amyloidoses by illuminating the dynamic nature of structurally and functionally variant protein aggregates and defining the cellular and biophysical parameters that underlie their function with different models including yeast, animal models, and human organoids.

Topics to be covered:

- How do amyloid strains form and spread?
- Are there common structural dynamics to proteopathic amyloid strains?
- Are there cell type-specific impacts of amyloidogenic strains on brain functions?
- How is structure linked to Ab and tau phenotypes, pathologies, and cross-seeding capabilities?
- How can yeast, animal models, and human organoids report on pathobiology
- How to translate pathobiology of amyloid strains for therapeutics?

Workshop Leaders

David Lynn
HHMI Professor
Emory University

Zhexing Wen
Assistant Professor
Emory University

12.30 | 9.30 Lunch & Virtual Speed Networking

Workshop B

1.30 | 10.30

Opportunities for Pharmacological Manipulation of the Ubiquitin Proteasome System from PROTACS to Proteasome Enhancement

Enabled by the exciting clinical progression of PROTAC-based therapies, our understanding of the pharmacological opportunity held by the ubiquitin proteasome system has taken a giant leap in recent years. Still, our limited knowledge of fundamental biology and chemistry is hindering the ongoing efforts to translate robust candidates into the clinic. In this workshop, we will cover the vital technical scientific challenges that need to be addressed to accelerate successful PROTAC therapies through the clinic in the future. Also, we will discuss the opportunities and findings on targeting protein degradation using the latest PROTAC approaches.

Topics to be covered:

- How can the ubiquitin system be cooped for targeted protein degradation?
- How can protein targeting chimeric molecule (PROTACS) be used to target specific proteins for degradation?
- Can proteasome capacity be upregulated?
- Can ubiquitin dependant protein degradation be enhanced?
- How can degradation of intrinsically disordered proteins (IDPs) be stimulated?

Workshop Leaders

David Smith
Associate Professor
West Virginia University

Behnam Nabet
Postdoctoral Research Fellow,
Gray Lab
Dana-Farber Cancer Institute

CONFERENCE DAY ONE
WEDNESDAY | OCTOBER 28

9.30AM - 4.00PM EDT | 6.30AM - 1.00PM PDT

8.30 5.30 **Online Registration & Virtual Networking**

8.55 5.55 **Chairperson's Opening Remarks**

Developing Conformation-Specific & Agnostic Therapeutics Against Misfolded & Oligomeric Proteins

9.00 6.00 **Small Molecule Inhibitors of a Common Conformational Morphology Identified in Intrinsically Disordered Proteins**

Marcia Taylor
VP Research & Neurodegeneration Alliance Manager
Treventis

- Common Conformational Morphology (CCM) acts as an in silico crystal structure for IDPs
- Hit identification has been performed for alpha synuclein, amylin, amyloid beta, and tau
- Demonstrated dose dependent decrease in oligomeric species of amyloid beta and tau

9.30 6.30 **Amyloid Removal Therapy for Systemic Amyloidosis**

Aubin Michalon
Principal Scientist
Neurimmune

- Generation of amyloid selective antibodies from human immune memory repertoires
- Lead selection and PoC studies with focus on assays with high translational value
- Modeling treatment response to support clinical trial design

10.00 7.00 **Regulation of Proteostasis Networks in Aging & Disease**

Rick Morimoto
Professor
Northwestern University

- Understanding how the proteostasis network is established in development to protect through reproduction and fails in adulthood and ageing
- Mapping out the course of events, including chaperone sequestration, that perpetuate protein aggregation and misfolding – what markers might be predictive of age-associated disease?
- Investigating the systemic consequence and communication of protein misfolding between tissues

10.30 7.30 **Exploring Conformational Changes and Multimerization of Proteins With a High-Throughput Conformation Biosensor**

Ulrich Rant
CEO
Dynamic Biosensors

- Analysis of conformational changes in proteins induced by the binding of small molecules
- Real-time monitoring of multimerization and aggregation processes
- Discrimination of different ubiquitinylation states
- Description of high-throughput workflows with the heliX® biosensor

10.45 7.45 **Speed Networking & Morning Break**

Reinventing the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new and lasting connections!

11.50 8.50 **Examining the Effects of Sonication on Alpha Synuclein Pre-Formed Fibrils (PFFs)**

Ariel Louwrier
President & CEO
StressMarq Biosciences Inc.

- Alpha synuclein and tau pre-formed fibrils (PFFs) are useful tools for modelling neurodegenerative diseases. Various types can be generated with different properties
- PFFs need to be sonicated prior to introducing them to cellular or animal models in order to generate disease pathology. This was originally thought to be because sonication reduces fibril length.
- Our data shows that solubility and fibril length both change with sonication. Increased solubility is more likely to account for the increased potency of oligomers and certain fibril types

Michele Vendruscolo
Professor & CSO
Cambridge University Centre for Misfolding Diseases & **Wren Therapeutics**

12.00 9.00

Rational Design of Conformation-Specific Antibodies Targeting Protein Aggregates

- Discussing why protein oligomers are challenging targets for antibody discovery
- Presenting a method of antibody discovery for these targets
- Exploring how these antibodies can be used for diagnostics and therapeutics

12.30 9.30

Engineered Chaperone Therapeutics: Transformative Therapeutics for Repairing Protein Misfolding of Conformational Diseases

Akinori Hishiya
Founder & CSO
SOLA Biosciences

- SOLA is a biotherapeutics company focusing on developing transformative therapies which enable the specific protein folding for disease-causing proteins
- SOL-01 diminishes aggregation of mutated huntingtin proteins without affecting wild-type huntingtin proteins, and SOL-02 suppresses misfolded alpha-synuclein proteins
- SOLA's science team designs the technology for targeted protein folding. SOLA is looking for collaborators and partners to accelerate the therapeutic development

12.50 9.50 **Speed Networking & Lunch Break**

Identifying Novel Therapeutics Using Innovative Drug Discovery Approaches

1.50 10.50

Antiviral Approaches Targeting Proteostasis are Safe, Effective and Do Not Elicit Drug Resistance

Judith Frydman
Professor
Stanford University

- Viruses are hyper-dependent on the host proteostasis machinery
- This provides an opportunity to develop broad spectrum antivirals that do not elicit drug resistance

2.20 11.20

A Network Kinetics Drug Discovery Strategy for Targeting Protein Aggregation

Johnny Habchi
Head of Research
Wren Therapeutics

- Protein aggregation is a kinetics process, therefore kinetics readouts are needed
- Unravelling the mechanism of protein aggregation using chemical kinetics at a detailed microscopic level provides us with an exceptional opportunity of a controlled intervention and consequently leads to a selective targeting of the toxic species
- The quantitative and predictive power of chemical kinetics allows for a systematic optimization of therapeutics molecules with desired properties

2.50 11.50

Cross-Learnings from Mechanisms of Action Underlying Protein Conformational Disorders

Christopher Missling
President & CEO
Anavex Life Sciences

- How to evaluate the safety and tolerability of novel protein misfolding therapeutics as assessed through clinical development
- How can the commonalities in underlying molecular pathology be used to inform the development of new treatment options for protein-misfolding diseases?
- How can you leverage a clinical developmental strategy to address a range of diseases caused by protein misfolding for which no approved disease-modifying treatments currently exist?

3.20 12.20 **Afternoon Networking Break**

Optimizing Preclinical Models & Technologies for Robust Translation into the Clinic

3.50 12.50 **Discovery & Clinical Translation of a Small-Molecule Inhibitor of α-Synuclein Toxicity**

Robert Scannevin
VP, Discovery Biology
Yumanity

- Using a yeast-to-human phenotypic screening platform we recently discovered that small molecule inhibitors of stearoyl-coA-desaturase (SCD) potently protect cells from α-synuclein toxicity
- Preclinical data confirmed that reduction of fatty-acid desaturation is correlated with protection, providing a translational pharmacodynamic marker that can be used in animals and human studies
- Focusing on the preclinical discovery and recent Phase Ia human clinical data from our lead SCD inhibitor, YTX-7739

4.20 1.20 **Using Single Particle Detection Technologies to Quantify Pathological Tau in Extracellular Vesicles & Biofluids**

Matthew Townsend
Global Director of Proteostasis, Alzheimer's Disease
AbbVie

- Outlining methods development
- Discussing the value of exosome capture in distinguishing AD from control
- Comparing CSF and plasma

4.50 1.50 **Discussing ALZ-801 - A Phase 3 Ready Conformational Modifier with Disease Modifying for Alzheimer's Disease**

John Hey
CSO
Alzheon

- Presenting a small molecule modifier of protein misfolding through a novel "enveloping MOA"
- Discussing how these small molecule modifiers represent a promising new class of agents for neurodegenerative disease

5.20 2.20 **Chairperson's Closing Remarks**

5.30 2.30 **End of Day One of Protein Misfolding Drug Discovery Summit**

"The prion-like hypothesis in Alzheimer's and Parkinson's now has a substantial body of supporting evidence. This conference addresses how pharma/biotech plan to develop new therapies with this knowledge"

Matthew Townsend, Global Director of Proteostasis, Alzheimer's Disease, AbbVie

"Excited to share insights into advancement of clinical findings relevant to the scientific community and the patient population affected by the respective diseases"

Christopher Missling, President & CEO, Anavex Life Sciences

CONFERENCE DAY TWO
THURSDAY | OCTOBER 29

9.30AM - 3.30PM EDT | 6.30AM - 12.30PM PDT

9.00 6.00 **Virtual Coffee Networking**

9.20 6.20 **Chairperson's Opening Remarks**

Exploring Different Molecular Approaches of Targeting Misfolded, Oligomeric & Aggregated Proteins

9.30 6.30 **Embarking on a New Era of Immunotherapy for Proteinopathies**

Wagner Zago
CSO
Prothena

- Focusing on the evidence that antibodies can reduce extracellular and intraneuronal accumulation of protein aggregates and prevent neurodegeneration
- Reviewing the current clinical landscape of immunotherapeutics being tested in neurodegenerative diseases

10.00 7.00 **Role of Gut Microbiota-Derived Compound(S) in A-Synuclein Misfolding and C9orf72 Hexanucleotide Repeat Expansion as Novel Therapeutic in Parkinson-Plus Syndromes**

Giulio Pasinetti
Chair & Professor of Neurology
Icahn School of Medicine at Mount Sinai

- Learning the mechanism through which microbiome derived polyphenolic metabolites may attenuate seeding and α -synuclein
- Discussing the role of the gut-brain axis in promotion in mechanism associated to protein misfolding in models of Parkinson plus such as frontotemporal dementia, cortico-basal degeneration, etc)
- Discussing the potential role of gut microbiota-derived dietary polyphenolic compound(s) to increase the likelihood of therapeutic efficacy in Parkinson-plus syndromes

10.30 7.30 **Use of High Content Screening to Identify Conformation Modulators as Therapeutics for Huntington's Disease**

Beth Hoffman
Founder, President & CEO
Origami Therapeutics

- Phenotypic assays enabled identification of small molecules that prevent disease-causing mutated huntingtin aggregation
- Deconvolution of phenotypic screening to determine mechanism of action
- The use of chemo-phenomics and patient-derived model systems to select and optimize leads with therapeutic potential

11.00 8.00 **Speed Networking & Morning Break**
Reinventing the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new and lasting connections

Highlighting Different Modalities in Development for Protein Conformational Disorders

11.30 8.30 **Precision Immunotherapies for Protein Misfolding Diseases: The ProMIS Platform**

Neil Cashman
CSO & Co-Founder
ProMIS Neurosciences

- Toxic, propagating misfolded proteins underlie neurodegeneration
- Antibodies directed against protein misfolding-selective epitopes can neutralize toxicity and propagation in disease

12.00 9.00 **Targeting the Intrinsically Disordered State of Tau & Alpha-Synuclein By Small Molecules as a Therapeutic Strategy for Alzheimer's & Parkinson's Disease**

Gergely Tóth
Founder & CEO
CantaBio Pharmaceuticals

- Intrinsically disordered tau and alpha-synuclein are viable receptors of drug-like small molecules
- Application of computer-aided structure based and biophysical screening paradigms resulted in the discovery of novel small molecule ligands to tau and alpha-synuclein
- Targeting the monomeric state of intrinsically disordered proteins by small molecules to reduce their misfolding and aggregation is a feasible therapeutic approach

12.30 9.30 **Speed Networking & Lunch Break**

1.30 10.30 **Translating Exciting Science into Clinical Success in Parkinson's Disease; Examples of Synuclein & Glucocerebrosidase Targeting**

Peter Lansbury
CSO
Lysosomal Therapeutics

- Biomarkers for drug action in the brain are considered to be necessary for big pharma - are they really?
- Addressing how selection of patients for early trials is the most important issue
- Discussing why the connection between synuclein and Parkinson's disease is not as clear as you have been led to believe

Assessing the Viability of Therapeutics Targeting Misfolded & Oligomeric Proteins in a Competitive Market

2.00 11.00 **Panel Discussion: Conducting a Strategic Analysis of Protein Misfolding Therapeutics**

- What key learnings can be applied from clinical successful companies in this space?
- What change do you want to see in this space from both large pharma and biotech companies to accelerate robust candidates into the clinic?
- Where are the key opportunities for money flow, partnerships and collaborations to accelerate scientific progress?
- What is the market opportunity and unmet need that makes protein misfolding therapeutics an attractive but high hanging fruit in terms of therapeutic potential?

Robert Scannevin
VP, Discovery Biology
Yumanity

Neil Cashman
CSO & Co-Founder
ProMIS Neurosciences

Gergely Tóth
Founder & CEO
CantaBio Pharmaceuticals

Christopher Missling
President & CEO
Anavex Life Sciences

3.00 12.00 **Chairperson's Closing Remarks & Close of Protein Misfolding Drug Discovery Summit**

"We now face a critical transition in our understanding of intrinsically disordered protein (IDP) domains in eukaryotic cells, from how they process information to their impact on disease. This transition must be catalyzed by industrial and academic collaboration if we are to successfully address the growing threat of protein misfolding diseases as our population ages"

David Lynn, HHMI Professor, Emory University

PARTNER WITH US

As we continue to adapt considering the global public health situation, the **Digital Protein Misfolding Drug Discovery Summit** offers a unique opportunity to continue collaborating with decision makers in the field. We'll work with you to build bespoke partnerships to ensure you meet your 2020 business objectives.

Below are some of the unique opportunities available through the digital summit.

Secure a virtual exhibition booth to **showcase your expertise and educate the industry on how you can support their R&D**

Leverage targeted online networking to **facilitate lead generation and build new relationships with senior level decision makers from leading pharma and biotech companies**

Secure a branding or speaking opportunity to **demonstrate your thought leadership, drive your brand exposure and differentiate yourself from competitors**

Innovation Partner

StressMarq Biosciences is a research reagents company manufacturing antibodies, proteins, ELISA kits, and small molecules. It is currently the only company worldwide that manufactures active recombinant alpha synuclein and tau fibrillar "seeds" that can generate Lewy body and tau pathologies, respectively. These have become increasingly popular in generating neurodegenerative disease models. Additionally, StressMarq has pursued patent protection for an antibody with alpha synuclein aggregation neutralization capability, resulting in a therapeutic candidate for Parkinson's and Alzheimer's. **www.stressmarq.com**

Innovation Partner

Dynamic Biosensors is a provider of instruments, consumables, and services in the field of analytical systems for the characterization of biomolecules and molecular interactions. We are headquartered in Martinsried, south of Munich / Germany, a vital center of Europe's biotechnology industry. Dynamic Biosensors commercializes switchSENSE® technology, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development. The switchSENSE® technology is protected worldwide and only available through Dynamic Biosensors. **www.dynamic-biosensors.com**

Innovation Partner

SOLA is a biotherapeutics company focusing on developing transformative therapies to treat protein misfolding diseases. SOLA's technology is designed to harness the power of a patient's own chaperones to repair disease-causing proteins. Our innovative engineered chaperone technology enables the repairing of misfolded proteins which cause devastating neurogenerative diseases such as Huntington and Parkinson's diseases. **www.sola-bio.com**

GET INVOLVED

Jacob Roberts-Kendall
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.protein-misfolding.com

Tel: +1 617 455 4188

Email: register@hansonwade.com

SAVE valuable time and resources by learning how the leading companies in the space are advancing their pipeline of therapeutics targeting misfolded and oligomeric proteins

GAIN first-hand insights on challenges and strategies on how to robustly translate promising protein misfolding targeted therapeutics into clinical development and increase your success rate

FORM lasting connections by engaging directly with colleagues from the leading pharma and biotech companies actively developing protein misfolding targeted therapeutics and seeking the best solutions, in an intimate environment

Please select appropriate price when booking. Bookings are subject to approval.

Industry Pricing	Register & Pay by Friday, July 31 **(SAVE UP TO $600)**	Standard Pricing
Conference + 2 Workshops	$2,247	$2,847
Conference + 1 Workshop	$1,998	$2,448
Conference Only	$1,749	$2,049
Workshop Only	$349	$499

Academic Pricing	Register & Pay by Friday, July 31 **(SAVE UP TO $600)**	Standard Pricing
Conference + 2 Workshops	$1,747	$2,347
Conference + 1 Workshop	$1,548	$1,998
Conference Only	$1,349	$1,649
Workshop Only	$299	$449

*Please note: If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge you will have the option to provide your VAT number and the charge will be automatically deducted at checkout. Visit the website for more details.

Team Discounts

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 + delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Code: 16466